Next-generation facility will support growth of startups and accelerate early-stage innovation with state-of-the-art research infrastructure, scientific and business support
CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)--
BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and affordable medicines, today announced the official launch of the BeiGene Bioisland Innovation Center (BIC) in Guangzhou, China to enable scientists and entrepreneurs to accelerate development of highly differentiated, cutting-edge medical innovations. The BIC is an innovator-centric incubator built on BeiGene’s goal of supporting exploration of new paths to meet patient needs around the world.
“Over a decade ago, we started BeiGene’s journey by following the science and have grown to be a global biotechnology company with capabilities across the full value chain. With the BIC, we are supporting entrepreneurs with similar purpose and vision of delivering innovation that will benefit more patients worldwide. We expect the center will also contribute to our innovation pipeline,” remarked John V. Oyler, Co-Founder, Chairman and CEO of BeiGene.
“Science and innovation are BeiGene’s core strengths. We are committed to supporting entrepreneurs incubate bold, new ideas into impactful programs that will create value for patients and benefit patients globally,” added Xiaodong Wang, M.D., Co-Founder of BeiGene, Chairman of the Company’s Scientific Advisory Committee. “With our scientific research, unique clinical development capabilities, and footprint, BeiGene is well positioned to explore new paths of innovation and support new talents in the booming biotechnology hub of Guangzhou’s Greater Bay Area.”
Innovator-Centric Incubator to Accelerate Growth and Possibilities
The BIC is located in the Guangdong-Hong Kong-Macau Greater Bay Area, an emerging global biotechnology hub, and will feature a comprehensive research infrastructure and professional management team. The incubator will be equipped with state-of-the-art laboratory infrastructure and comprehensive research capabilities that enable scientists and entrepreneurs to get their ideas off the ground. In addition, scientists and entrepreneurs at the BIC will have potential access to support from BeiGene on full industry value chain integration.
The comprehensive, advanced technology platform at the BIC will allow innovators more autonomy in development, and integrated services to position them for growth.
“The BIC is focused on cultivating entrepreneurship for new biotech companies with a passion for transformational medicines, diagnostics and medical devices that can help address unmet needs, and advancing breakthrough innovations from early discovery to being accessed by patients all over the world,” said Jonathan Liu, Chief Executive of Bioisland Initiative and Chairman of the Board of BeiGene Biologics Co., Ltd.
Dr. H. Fai Poon. CEO of Zhongshan Quacell Biotechnology Co., Ltd., which is part of the innovation center, commented, "We share the same beliefs of the model and concept of the BeiGene Bioisland Innovation Center. This kind of international collaboration not only accelerates technical innovation for small and medium-sized enterprises, but also provides suitable platforms and resources to commercialize these innovations. For Quacell, which also has the 'innovative DNA', to be part of the BIC provides the opportunity to communicate and cooperate with many innovative companies in different fields around the world. We look forward to creating a common path for each other's future research and development. And we believe that this path leads to infinite possibilities to upgrade and even revolutionize the industry."
BeiGene is a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide. With a broad portfolio of more than 40 clinical candidates, we are expediting development of our diverse pipeline of novel therapeutics through our own capabilities and collaborations. We are committed to radically improving access to medicines for two billion more people by 2030. BeiGene has a growing global team of approximately 8,000 colleagues across five continents. To learn more about BeiGene, please visit www.beigene.com and follow us on Twitter at @BeiGeneGlobal.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding BeiGene’s plans and aspirations regarding the BIC, and BeiGene’s plans, commitments, aspirations and goals under the headings “BeiGene Oncology” and “About BeiGene”. Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including BeiGene's ability to demonstrate the efficacy and safety of its drug candidates; the clinical results for its drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; BeiGene's ability to achieve commercial success for its marketed medicines and drug candidates, if approved; BeiGene's ability to obtain and maintain protection of intellectual property for its medicines and technology; BeiGene's reliance on third parties to conduct drug development, manufacturing and other services; BeiGene’s limited experience in obtaining regulatory approvals and commercializing pharmaceutical products and its ability to obtain additional funding for operations and to complete the development and commercialization of its drug candidates and achieve and maintain profitability; the impact of the COVID-19 pandemic on BeiGene’s clinical development, regulatory, commercial, and other operations, as well as those risks more fully discussed in the section entitled “Risk Factors” in BeiGene’s most recent quarterly report on Form 10-Q as well as discussions of potential risks, uncertainties, and other important factors in BeiGene's subsequent filings with the U.S. Securities and Exchange Commission. All information in this press release is as of the date of this press release, and BeiGene undertakes no duty to update such information unless required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211220005233/en/
+1 240 410 0129